Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
14 Machi 2021 14:44:11
Azithromycin na ujauzito
Azithromycin, ni dawa ya azalide inayotokana na erythromycin. Dawa hii ipo kundi la dawa zinazoitwa macrolide ikijumuisha clarithromycin na erythromycin. Taarifa za ujauzito wa binadamu, hauonyeshi kuwa dawa hii inasababisha madhara ya kiuumbaji kwa mtoto.
Ushauri dhidi ya matumizi kwa mama mjamzito
Inapatana na ujauzito
Inapatana na ujauzito maana yake ni nini?
Uzoefu wa matumizi kwa binadamu kuhusu dawa hii au dawa zingine zilizo kundi moja au zenye kufanya kazi kwa utaratibu unaofanana, zinatosha kuonyesha kuwa, madhara kwa kichanga tumboni ni madogo sana au hakuna kabisa. Tafiti za uzazi kwa wanyama hazina uhalisia kwa binadamu.
Ushauri wa matumizi kwa mama anayenyonyesha
Inapatana na kunyonyesha
Inapatana na kunyonyesha maana yake ni nini?
Kiasi kidogo cha dawa hii kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Dawa hii haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:21:36
Rejea za mada hii
1. Ramsey PS, et al. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol 2003;188:714–8.
2. Heikkinen T, et al. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. Br J Obstet Gynaecol 2000;107:7705.
3. Edwards M, et al. Comparison of azithromycin and erythromycin for Chlamydia cervicitis in pregnancy (abstract). Am J Obstet Gynecol 1994;170:419.
4. Bush MR, et al. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet Gynecol 1994;84:61–3.
5. Rosenn M, et al. A randomized trial of erythromycin and azithromycin for the treatment of chlamydia infection in pregnancy (abstract). Am J Obstet Gynecol 1996;174:410.
6. Wehbeh H, et al. A randomized clinical trial of a single dose of azithromycin in the treatment of chlamydia among pregnant women (abstract). Am J Obstet Gynecol 1996;174:361.
7. Wehbeh HA, et al. Single-dose azithromycin for chlamydia in pregnant women. J Reprod Med 1998;43:509–14.
8. Ogasawara KK, Goodwin TM. Efficacy of azithromycin in reducing lower genital ureaplasma colonization in women at risk for preterm delivery (abstract). Am J Obstet Gynecol 1997;176:S57.
9. Choi EK, et al. Azithromycin therapy for scrub typhus during pregnancy. Clin Infect Dis 1998;27:1538–9.
10. Wilton LV, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882–9.
11. Tellem Ret al. Pregnancy outcome after gestational exposure to the new macrolides: a prospective controlled cohort study (abstract). Reprod Toxicol 2005;20:484.
12. Sarkar M, et al. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006;6:18. [Epub 2006 May 30].
13. Cooper WO, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol 2009;23:18–28.
14. Cerar D, et al. Azithromycin for acute Q fever in pregnancy. Wien Klin Wochenschr 2009;121:469–72.
15. Wawer MJ, et al. Control of sexually transmitted disease for AIDS prevention in Uganda: a randomized community trial. Lancet 1999;353:525–35.
16. Gray RH, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol 2001;185:1209–17.
17. Kigozi GG, et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2003;189:1398–400.
18. Bar-Oz B, et al. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study. Eur J Obstet Gynecol Reprod Biol 2008;141:31–4.
19. Bar-Oz B,et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observations study. Drug Saf 2012;35:589–98.
20. Hauth JC, et al. Mid-trimester metronidazole and azithromycin did not prevent preterm birth in women at increased risk: a double-blind trial. Am J Obstet Gynecol 2001;185(6 Suppl):S86.
21. van den Broek NR, et al. The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta analysis. PloS Med 2009;6:e100091.
22. Sorensen HT, et al. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003;35:104–6.
23. Kelsey JJ, et al. Presence of azithromycin breast milk concentrations: a case report. Am J Obstet Gynecol 1994;170:1375–6.
24. Goldstein LH, et al. The safety of macrolides during lactation. Breastfeed Med 2009;4:157–200.